Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease
- PMID: 11823645
- DOI: 10.1126/science.1067389
Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease
Abstract
Parkinson's disease is a movement disorder characterized by degeneration of dopaminergic neurons in the substantia nigra pars compacta. Dopaminergic neuronal loss also occurs in Drosophila melanogaster upon directed expression of alpha-synuclein, a protein implicated in the pathogenesis of Parkinson's disease and a major component of proteinaceous Lewy bodies. We report that directed expression of the molecular chaperone Hsp70 prevented dopaminergic neuronal loss associated with alpha-synuclein in Drosophila and that interference with endogenous chaperone activity accelerated alpha-synuclein toxicity. Furthermore, Lewy bodies in human postmortem tissue immunostained for molecular chaperones, also suggesting that chaperones may play a role in Parkinson's disease progression.
Comment in
-
Neurobiology. Chaperones take flight.Science. 2002 Feb 1;295(5556):809-10. doi: 10.1126/science.1069544. Science. 2002. PMID: 11823628 No abstract available.
Similar articles
-
A Drosophila model of Parkinson's disease.Nature. 2000 Mar 23;404(6776):394-8. doi: 10.1038/35006074. Nature. 2000. PMID: 10746727
-
Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.J Neurochem. 2004 Oct;91(2):451-61. doi: 10.1111/j.1471-4159.2004.02728.x. J Neurochem. 2004. PMID: 15447678
-
alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10813-8. doi: 10.1073/pnas.152339799. Epub 2002 Jul 16. Proc Natl Acad Sci U S A. 2002. PMID: 12122208 Free PMC article.
-
Experimental models of Parkinson's disease.Nat Rev Neurosci. 2001 May;2(5):325-34. doi: 10.1038/35072550. Nat Rev Neurosci. 2001. PMID: 11331916 Review.
-
Alpha-synuclein and neurodegenerative diseases.Nat Rev Neurosci. 2001 Jul;2(7):492-501. doi: 10.1038/35081564. Nat Rev Neurosci. 2001. PMID: 11433374 Review. No abstract available.
Cited by
-
Protein tyrosine phosphatase receptor type O serves as a key regulator of insulin resistance-induced α-synuclein aggregation in Parkinson's disease.Cell Mol Life Sci. 2024 Sep 14;81(1):403. doi: 10.1007/s00018-024-05436-4. Cell Mol Life Sci. 2024. PMID: 39276174 Free PMC article.
-
Tissue-specific landscape of protein aggregation and quality control in an aging vertebrate.Dev Cell. 2024 Jul 22;59(14):1892-1911.e13. doi: 10.1016/j.devcel.2024.04.014. Epub 2024 May 28. Dev Cell. 2024. PMID: 38810654
-
Biochemical Fractionation of Human α-Synuclein in a Drosophila Model of Synucleinopathies.Int J Mol Sci. 2024 Mar 25;25(7):3643. doi: 10.3390/ijms25073643. Int J Mol Sci. 2024. PMID: 38612454 Free PMC article.
-
Genetic modifiers of synucleinopathies-lessons from experimental models.Oxf Open Neurosci. 2023 Mar 9;2:kvad001. doi: 10.1093/oons/kvad001. eCollection 2023. Oxf Open Neurosci. 2023. PMID: 38596238 Free PMC article. Review.
-
Elevated α-synuclein levels inhibit mitophagic flux.NPJ Parkinsons Dis. 2024 Apr 9;10(1):80. doi: 10.1038/s41531-024-00696-0. NPJ Parkinsons Dis. 2024. PMID: 38594264 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous
